Literature DB >> 25123754

Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab.

Charles L Bennett1, Scott D Newsome, Oliver Sartor, Kenneth R Carson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25123754      PMCID： PMC4440419          DOI： 10.1002/cncr.28947

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

Review 1.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

2.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Authors:  Kenneth R Carson; Andrew M Evens; Elizabeth A Richey; Thomas M Habermann; Daniele Focosi; John F Seymour; Jacob Laubach; Susie D Bawn; Leo I Gordon; Jane N Winter; Richard R Furman; Julie M Vose; Andrew D Zelenetz; Ronac Mamtani; Dennis W Raisch; Gary W Dorshimer; Steven T Rosen; Kenji Muro; Numa R Gottardi-Littell; Robert L Talley; Oliver Sartor; David Green; Eugene O Major; Charles L Bennett
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

Review 3.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Kenneth R Carson; Daniele Focosi; Eugene O Major; Mario Petrini; Elizabeth A Richey; Dennis P West; Charles L Bennett
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316
  3 in total
  1 in total

1.  Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.

Authors:  Dennis W Raisch; John A Rafi; Cheng Chen; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2016-06-20       Impact factor: 4.250
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.